Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB104 in Cognitive Impairment Associated With Schizophrenia
NCT03745820Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of pesampator in schizophrenia, sponsored by Biogen. Started Nov 2018; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03745820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745820.